GlassScriptPhysician profile
Jordon Prosapio
NPI 1740854405
$1,468.71
in general payments reported to CMS, 2019-2025
16 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.78 · 2021: $92.02 · 2022: $33.08 · 2023: $328 · 2024: $607 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $416.67 | 2024-2025 | Briviact, Nayzilam |
| Atricure, INC. | $172.04 | 2023 | |
| Neurocrine Biosciences, INC. | $167.39 | 2024-2025 | Ingrezza |
| Ani Pharmaceuticals, INC. | $149.76 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $142.98 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $106.35 | 2023 | Quviviq |
| Eisai INC. | $80.08 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $42.64 | 2024 | |
| Lilly USA, LLC | $35.07 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $34.54 | 2023-2024 | Ultomiris |
| Tg Therapeutics, INC. | $31.96 | 2024 | |
| Amgen INC. | $25.32 | 2024 | Uplizna |
| Supernus Pharmaceuticals, INC. | $19.74 | 2024 | Qelbree |
| Sk Life Science, INC. | $19.39 | 2023 | |
| Emd Serono, INC. | $17.37 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $7.41 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordon Prosapio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.